Brachytherapy最新文献

{"title":"PO79","authors":"Joel Beaudry, Gil'ad N. Cohen, Marisa Kollmeier, Daniel Gorovets, Michael Zelefsky, Antonio L. Damato","doi":"10.1016/j.brachy.2023.06.180","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.180","url":null,"abstract":"Purpose Promising results have been demonstrated using single fraction external beam for treatment of prostate cancer. Due to inherent differences of delivery between external beam and brachytherapy, the feasibility of replicating the external beam dosimetry in brachytherapy is investigated. Materials and Methods A retrospective study was performed using datasets of 120 HDR prostate patients from 6 different physicians in a single institution. The original plans were prescribed to 15Gy (with EBRT to follow). No changes were made to catheter placement, dwell positions, or contours. An in-house software, a linear optimizer with bounded and unbounded constraints, was used to elevate the dose to the entire gland to 24 Gy with no manual manipulation of the optimized plan/dwell times. The resulting plans were compared with published results of single fraction external beam plans to a dose of 24Gy, using the same dosimetric constraints [1]. Prostate D50%, Dmean, D95%, D2%, V24Gy, and V21.6Gy were reported, as well as OAR constraints D1cc for the rectum and urethra. Results Brachytherapy vs external beam prostate median metrics were 31.4 vs 24.5 Gy for Dmean; 22.1 vs 22.1 Gy for D95%; 79.8 vs 84.8% for V24Gy; 96.2 vs 96.2% for V21.6Gy. D1cc median metrics were 10.6 vs 18.5Gy for urethra and 18.2 vs 18.8Gy for rectum. Conclusion Dose escalation to the prostate was feasible and achieved similar results to external beam single fraction radiotherapy in terms of target coverage and OAR constraints. Due to the inherent differences of radiation delivery, the dose distributions differ primarily in hotspots and non-homogeneity that could lead to clinical differences. Delivery uncertainty is believed to be lower in brachytherapy, resulting in shrinking of margins and more accurate placement and delivery of hotspots, if desired. The retrospective study was based upon fixed prior implant geometries, therefore further work to investigate the placement of needles to further optimize dose conformality is ongoing. [1] Greco C et al. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial. JAMA Oncol. 2021 May 1;7(5):700-708. Promising results have been demonstrated using single fraction external beam for treatment of prostate cancer. Due to inherent differences of delivery between external beam and brachytherapy, the feasibility of replicating the external beam dosimetry in brachytherapy is investigated. A retrospective study was performed using datasets of 120 HDR prostate patients from 6 different physicians in a single institution. The original plans were prescribed to 15Gy (with EBRT to follow). No changes were made to catheter placement, dwell positions, or contours. An in-house software, a linear optimizer with bounded and unbounded constraints, was used to elevate the dose to the entire gland to 24 Gy with no manual manipulation of the","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO107","authors":"Zhe Ji, Yang Ni, Chuang He, Xuequan Huang, Xin Ye, Junjie Wang","doi":"10.1016/j.brachy.2023.06.208","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.208","url":null,"abstract":"Purpose To compare the efficacy and safety of radioactive I-125 seed ablation brachytherapy (RSABT) and microwave ablation therapy (MWAT) in the treatment of inoperable early non-small cell lung cancer. Materials and Methods The data of patients with early non-small cell lung cancer who received CT guided RSABT and MWAT in our collaborative group from December 2010 to November 2020 were included. The main outcome measure was progression free survival, and the secondary outcome measures were overall survival rate and adverse events. Kaplan-Meier methods were used to analyze progression free survival and overall survival. Logistic and Cox regression were used for univariate and multivariate analysis, respectively. Results The median follow-up time of patients in RSABT and MWAT groups were 47.4 months and 60 months, respectively. Progression free survival (PFS) in the RSABT group was better than that in the MWAT group. The 1-year, 3-year and 5-year PFS of RSABT and MWAT group were 87.3%, 72.6%, 65.8% and 89.5%, 69.3% and 43.7% respectively (P = 0.011); the overall survival (OS) of RSABT group was slightly better than MWAT group. The 1-year, 3-year and 5-year OS of the two groups were 97.2%, 78.1%, 66.1% and 99%, 75.8% and 55% respectively (P = 0.112). Treatment technology was also an independent factor affecting PFS (HR 0.48, 95%CI 0.28-0.83, P=0.008) in multivariate Cox analysis. And gender and T stage were independent factors affecting PFS and OS (P < 0.05). There are no fatal operation related complications. Pneumothorax was the most common complication. The incidence of MWAT group was slightly higher than that of RSABT group, which were 50% and 39% respectively (P = 0.313). The incidence of pleural effusion in MWAT group was higher than that in RSABT group (44% and 14%, respectively, P < 0.001). The incidence of needle bleeding in RSABT group was higher than that in MWAT group (32% and 5%, respectively, P < 0.001). Conclusions The outcomes of RSABT in the treatment of early NSCLC is no less than MWAT, and the incidence of operation complications is also equivalent to MWAT, but further exploration is needed. To compare the efficacy and safety of radioactive I-125 seed ablation brachytherapy (RSABT) and microwave ablation therapy (MWAT) in the treatment of inoperable early non-small cell lung cancer. The data of patients with early non-small cell lung cancer who received CT guided RSABT and MWAT in our collaborative group from December 2010 to November 2020 were included. The main outcome measure was progression free survival, and the secondary outcome measures were overall survival rate and adverse events. Kaplan-Meier methods were used to analyze progression free survival and overall survival. Logistic and Cox regression were used for univariate and multivariate analysis, respectively. The median follow-up time of patients in RSABT and MWAT groups were 47.4 months and 60 months, respectively. Progression free survival (PFS) in the RSABT group wa","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"74 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO69","authors":"Brian J. Moran, Roksana Tech, Jessica Manzella","doi":"10.1016/j.brachy.2023.06.170","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.170","url":null,"abstract":"Purpose Standard of care for localized prostate cancer is either surgical or radiotherapeutic. While total gland ablation was intended, recent efforts of certain institutions using cryotherapy or HIFU (High-Intensity Focused Ultrasound) have explored the efficacy of focal therapy for select patients. Diagnostic technology has evolved and improved the ability and accuracy to identify tumor extent and location. This analysis investigates low-dose-rate (LDR) focal prostate brachytherapy PSA outcomes by demonstrating impact and thus correlation with focal target volume. Method 132 patients, mean age 73.5 years old (range 48-89 y/o), underwent focal therapy using LDR prostate brachytherapy from 12/2007 - 2/2019. Patients were categorized as low (63/132, 47.7%), intermediate (55/132, 41.7%), or high (14/132, 10.6%) risk groups using D'Amico risk group stratification. Prescribed dose to focal target volume was 115Gy, 125Gy, 144Gy for Cs-131 (66/132, 50%), Pd-103 (1/132, 0.8%), and I-125 (65/132, 49.2%) respectively. Results Mean preplan focal target volume was 21.5cc (range 7.5-58.2cc). Mean planning total prostate volume was 63.1cc (range 18.1-143.1cc). Mean preplan focal target volume of the prostate, as a percentage of total prostate volume, was 30.6%. Median follow up was 20.2 months (range 1- 134 months). Focal brachytherapy greater than 1-year follow up, the PSA was impacted by a mean of 59.2% from initial PSA (95% Confidence Interval [58.7, 59.7]). Conclusion Focal LDR prostate brachytherapy may offer a more conservative therapeutic option for localized prostate cancer in select patients. For patients found to have recurrence of disease in the treated volume, or new disease identified in the untreated prostate volume, should be amenable to numerous salvage therapies. With further analysis, additional investigation will evaluate quality of life impact and dosimetric considerations. This analysis warrants further exploration of the role of LDR prostate brachytherapy treatment of select patients with localized prostate cancer. Standard of care for localized prostate cancer is either surgical or radiotherapeutic. While total gland ablation was intended, recent efforts of certain institutions using cryotherapy or HIFU (High-Intensity Focused Ultrasound) have explored the efficacy of focal therapy for select patients. Diagnostic technology has evolved and improved the ability and accuracy to identify tumor extent and location. This analysis investigates low-dose-rate (LDR) focal prostate brachytherapy PSA outcomes by demonstrating impact and thus correlation with focal target volume. 132 patients, mean age 73.5 years old (range 48-89 y/o), underwent focal therapy using LDR prostate brachytherapy from 12/2007 - 2/2019. Patients were categorized as low (63/132, 47.7%), intermediate (55/132, 41.7%), or high (14/132, 10.6%) risk groups using D'Amico risk group stratification. Prescribed dose to focal target volume was 115Gy, 125Gy, 144Gy for Cs-131 (66/132","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO06","authors":"Sudharshan Gupta, Vyshnava Mytri, Harjot Kaur Bajwa","doi":"10.1016/j.brachy.2023.06.107","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.107","url":null,"abstract":"Purpose To compare the dosimetric parameters of IC/IS brachytherapy vs Intracavitary brachytherapy in carcinoma cervix. Methods and Materials Patients diagnosed as carcinoma cervix and treated with radical chemoradiation (50Gy in 25 fractions) were included for analysis. Brachytherapy was performed using fletcher style tandem and ovoid applicator with interstitial component. The dose prescribed was 21Gy to HRCTV, 7Gy per fraction for 3 fractions. Three plans were created for comparison. First plan was the approved plan using combined IC/IS technique. Second plan was intracavitary plan with dose prescribed to point A using standard loading. Third plan was optimised intracavitary plan with dose prescribed to HRCTV. The dosimetric parameters analysed were D90 to HRCTV and D2cc to the OAR's Results 12 patients were included in this study. 50% patients had HRCTV volume >30cc. The mean D90 HRCTV was 87.2Gy in IC/IS plan, 84Gy in standard loading plan and 81.6Gy in optimized intracavitary plan. For patients with residual HRCTV>30cc, there was a significant difference between the D90 HRCTV among the three plans (p value=0.018). The mean D2cc to the bladder was 78.6Gy in IC/IS plan,94.1Gy in standard loading plan and 88.2Gy in optimized intracavitary plan. The mean D2cc to the rectum was 70.2Gy in IC/IS plan, 87.9Gy in standard loading plan and 80.2Gy (p value=0.034) in optimized intracavitary plan. The mean D2cc to the sigmoid was 63.9Gy in IC/IS plan, 69.8Gy in standard loading plan and 66.2Gy in optimized intracavitary plan. 50% of patients had HRCTV D90 target coverage less than 85Gy in standard loading plan. 33% of OAR constraints were achieved in optimised intracavitary plan. For HRCTV volumes>30 cc, average dose escalation to the D90 HRCTV was 4.7Gy compared to optimised intracavitary plan and 2.8 Gy compared to a standard loading plan Conclusion IC/IS brachytherapy was dosimetrically superior to intracavitary brachytherapy in patients with residual disease post EBRT. To compare the dosimetric parameters of IC/IS brachytherapy vs Intracavitary brachytherapy in carcinoma cervix. Patients diagnosed as carcinoma cervix and treated with radical chemoradiation (50Gy in 25 fractions) were included for analysis. Brachytherapy was performed using fletcher style tandem and ovoid applicator with interstitial component. The dose prescribed was 21Gy to HRCTV, 7Gy per fraction for 3 fractions. Three plans were created for comparison. First plan was the approved plan using combined IC/IS technique. Second plan was intracavitary plan with dose prescribed to point A using standard loading. Third plan was optimised intracavitary plan with dose prescribed to HRCTV. The dosimetric parameters analysed were D90 to HRCTV and D2cc to the OAR's 12 patients were included in this study. 50% patients had HRCTV volume >30cc. The mean D90 HRCTV was 87.2Gy in IC/IS plan, 84Gy in standard loading plan and 81.6Gy in optimized intracavitary plan. For patients with residual HRCTV>3","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO15","authors":"Ke Xu","doi":"10.1016/j.brachy.2023.06.116","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.116","url":null,"abstract":"Purpose To explore the factors influencing the short-term efficacy of 125I seed implantation in the treatment of perivascular lymph node metastasis of cervical cancer after radiotherapy and chemotherapy. Materials and Methods 30 patients with recurrent cervical cancer and perivascular lymph node metastasis after radiotherapy and chemotherapy, aged 28-76 years old, 16 cases of squamous cell carcinoma, 14 cases of adenocarcinoma, particle activity 0.4-0.7 mCi, peripheral dose 60-128 Gy, who were treated in our hospital from January 2006 to December 2018, were retrospectively analyzed, NRS was used to evaluate the improvement of pain and the occurrence of complications, single factor and multiple factor analysis were used to explore the factors affecting the efficacy, and the ROC curve was analyzed. Results All patients successfully completed the operation. The curative effect was evaluated in 6 months after the operation, including 14 cases of CR+PR and 16 cases of SD+PD. Univariate analysis: the size of lymph nodes and D90 immediately after the operation were the factors affecting the curative effect (P=0.001, 0.025). Multivariate analysis: tumor size was an independent pre-and post-factor affecting the curative effect (P=0.048). The ROC curve analysis showed that the longest diameter of lymph nodes was less than 4.85cm, and the prescription dose was greater than 76Gy, which was the best predictor of curative effect (AUC under the curve=0.853, 0.741; P=0.001, 0.025). The postoperative pain score was significantly reduced, and the difference was statistically significant (Z=-4.271, P<0.001). There was no fever, hemorrhage, bone marrow suppression, liver and kidney insufficiency, radiation skin and mucosa reaction in the follow-up of 6 months after operation Complications such as particle displacement. Conclusion 125I seed is safe and effective in the treatment of perivascular lymph node metastasis of cervical cancer after radiotherapy and chemotherapy. The short-term effect is better when the tumor length is less than 4.85 cm and the prescription dose is greater than 76 Gy. The long-term effect and complications need further study. To explore the factors influencing the short-term efficacy of 125I seed implantation in the treatment of perivascular lymph node metastasis of cervical cancer after radiotherapy and chemotherapy. 30 patients with recurrent cervical cancer and perivascular lymph node metastasis after radiotherapy and chemotherapy, aged 28-76 years old, 16 cases of squamous cell carcinoma, 14 cases of adenocarcinoma, particle activity 0.4-0.7 mCi, peripheral dose 60-128 Gy, who were treated in our hospital from January 2006 to December 2018, were retrospectively analyzed, NRS was used to evaluate the improvement of pain and the occurrence of complications, single factor and multiple factor analysis were used to explore the factors affecting the efficacy, and the ROC curve was analyzed. All patients successfully completed the operation. The","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"2012 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO123","authors":"Takashi Kawanaka, Chisato Tonoiso, Akiko Kubo, HItoshi Ikushima, Masafumi Harada","doi":"10.1016/j.brachy.2023.06.223","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.223","url":null,"abstract":"Purpose In Japan, cylindrical excisions are commonly performed in partial mastectomies for breast-conserving therapy, as opposed to the typical lumpectomies. Hence, when implementing Accelerated Partial Breast Irradiation (APBI) with the use of SAVI, a multi-lumen single catheter for partial breast irradiation with brachytherapy, discrepancies were noted between the shape of the excision cavity and the SAVI. Our institution reexamined the correlation between the form of the excision cavity and the shape of SAVI in instances of APBI that utilized post-operative SAVI insertion. To reconcile the discrepancy between the surgical cavity and the shape of the SAVI, we devised a hybrid APBI incorporating a supplementary catheter into the surrounding region of the SAVI and validated the dose distribution through simulation with a restricted quantity of supplementary catheters. Utilizing the obtained results, we present the outcomes of the hybrid APBI in actual clinical application. The objective of this investigation was to examine and augment the congruity between the SAVI applicator and the residual excision cavity following partial mastectomy in cases of APBI with SAVI in Japan. Materials and Methods Our evaluation encompasses four instances of APBI with postoperative insertion of SAVI, conducted at our institution between December 2018 and May 2019. The affected breasts included three right and one left, with two cases each affecting regions C and D. Through a postoperative insertion approach, each case was strategically placed from the inframammary fold. The treatment plan was executed using Oncentra brachy (Electa), with a prescribed dose of 34 Gy/10 Fr delivered through IPSA for PTV_EVAL. Our review of the outcomes prompted the implementation of hybrid APBI in three patients from the year 2020. Results The mean volume of the PTV_EVAL was observed to be 75.71 mL in the four cases of Accelerated Partial Breast Irradiation (APBI) with postoperative insertion of the SAVI applicator evaluated in this study. Out of these, three cases demonstrated a deviation of more than 10% in volume between the SAVI applicator and AIR, resulting in suboptimal dose delivery to the target volume (PTV_EVAL), which was evidenced by D90 failing to reach 90% in each case. Upon further analysis, the discrepancy was found to arise from the irregular shape of AIR on the chest wall side or bilaterally on the CT cross-section perpendicular to the SAVI, which had taken on a dog-ear form. To address this issue, a virtual hybrid APBI approach was implemented by adding one or two catheters placed along the SAVI applicator, leading to a substantial improvement in the D90 of PTV_EVAL in all three cases, reaching 90% in each. Based on this result, the hybrid approach was executed by inserting intra-tissue catheters near the prominent AIR, parallel to the SAVI applicator, under ultrasound guidance. The average D90 delivered by the SAVI alone was 74.39%, which improved to 95.90% with the ","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"27 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO14","authors":"Juan Wang, Yansong Liang, Hongtao Zhang, Jinxin Zhao","doi":"10.1016/j.brachy.2023.06.115","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.115","url":null,"abstract":"","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"59 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO113","authors":"Juan Wang, Zeyang Wang, Yansong Liang, Hongtao Zhang","doi":"10.1016/j.brachy.2023.06.214","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.214","url":null,"abstract":"Objective To evaluate the advantages and value of three-dimensional-printing template (3D-PT) guided 125I seed implantation for recurrent and metastatic cancer of head and neck. Methods 99patients(99 targets), received 125I seeds implantation at Heibei General hospital from Apr. 2015 to Feb. 2019 enrolled in this study. Patients were divided into two groups according to whether being guided by 3D-PT: Group A and Control B. A within-group comparison completed including the differences of the seeds number, target volume, and dosimetric parameters (D90, V90, V100 , and V150 ) between pre- and post-operative of the 2 groups, and between-group comparison including scan times, operation time, implantation time of each seed, the quality evaluation, local control rate (LCR), effective rate and complications in 2 and 3 months. Result The difference of scan times, operation time, implantation time of each seed of the two groups was significant (P<0.05). The within-group comparison of the seeds number, target volume, and dosimetric parameters in Group A (P>0.05) and the seeds number, target volume, D90, V90 of Group B(P>0.05) showed no statistically significant differences and V100 of pre- was greater than post-, V150 of post was greater than pre- in Group B (P<0.05) showed statistically significant differences. The postoperative V100 and preoperative V150 of Group A was greater than Group B (P<0.05), and the difference of rest index showed no statistically significant differences. The occurrence of puncture site pain of Group A was less than Group B, curative effect in 3 months of Group A was greater than Group B, and showed statistically significant difference (P<0.05).And the quality evaluation, curative effect and LCR in 2 monthsand3 months LCR, and postoperative hoarseness showed no statistically significant difference(P>0.05). Conclusion Comparing to CT-guidance, the application of 3D-PT can reduce the operation time and CT scan times, reduce complications and improve curative effect. To evaluate the advantages and value of three-dimensional-printing template (3D-PT) guided 125I seed implantation for recurrent and metastatic cancer of head and neck. 99patients(99 targets), received 125I seeds implantation at Heibei General hospital from Apr. 2015 to Feb. 2019 enrolled in this study. Patients were divided into two groups according to whether being guided by 3D-PT: Group A and Control B. A within-group comparison completed including the differences of the seeds number, target volume, and dosimetric parameters (D90, V90, V100 , and V150 ) between pre- and post-operative of the 2 groups, and between-group comparison including scan times, operation time, implantation time of each seed, the quality evaluation, local control rate (LCR), effective rate and complications in 2 and 3 months. The difference of scan times, operation time, implantation time of each seed of the two groups was significant (P<0.05). The within-group comparison of the seeds number, tar","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO102","authors":"Genghao Zhao, Huajian Wu, Wenyue Duan, Jinyu Wu, Liang Yang, Zhe Wang, Ruoyu Wang","doi":"10.1016/j.brachy.2023.06.203","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.203","url":null,"abstract":"Purpose This study aimed to assess the clinical efficacy and safety of Stereotactic ablative brachytherapy (SABT) for unresectable or inoperable head and neck cancers. Material and Methods This study retrospectively assessed the clinical data of 40 patients with unresectable or inoperable head and neck cancers treated with SABT from October 2016 to October 2021. The variables assessed were local efficacy, progression-free-survival (PFS) rate, overall survival (OS) rate, and radiological adverse effects. Results The median follow-up was of 34 months (range, 5-59 months), and PFS rate at 6, 12, and 24 months was 90.0%, 74.7%, and 66.3%, respectively. The median survival time was of 16 months [95% confidence interval (CI), 10.2-21.8 months] and the OS rate at 6, 12, and 24 months was 97.5%, 70.0%, and 34.6%, respectively. The results of the univariate analysis revealed that the type of pathology and GTV D90 were related to PFS rate (P<0.05). However, the type of pathology, GTV D90, age, and implantation site were related to OS rate (P<0.05). The results of the multivariate analysis revealed that the GTV D90 was related to PFS rate (P<0.05). The type of pathology and GTV D90 were related to OS rate (P<0.05). The evaluation of postoperative radiological adverse reactions revealed that seven cases (17.5%) developed grade I/II skin reactions, four cases (10.0%) developed grade I/II oral mucosal reactions, and no cases developed grade III or higher adverse reactions. Postoperative seed dislocation occurred in three patients with tongue cancer. Conclusions SABT has produced good local control and mild adverse reactions in the treatment of unresectable or inoperable head and neck cancers. Additionally, it is safe, feasible, minimally invasive, and has fewer adverse effects than other treatment modalities. This study aimed to assess the clinical efficacy and safety of Stereotactic ablative brachytherapy (SABT) for unresectable or inoperable head and neck cancers. This study retrospectively assessed the clinical data of 40 patients with unresectable or inoperable head and neck cancers treated with SABT from October 2016 to October 2021. The variables assessed were local efficacy, progression-free-survival (PFS) rate, overall survival (OS) rate, and radiological adverse effects. The median follow-up was of 34 months (range, 5-59 months), and PFS rate at 6, 12, and 24 months was 90.0%, 74.7%, and 66.3%, respectively. The median survival time was of 16 months [95% confidence interval (CI), 10.2-21.8 months] and the OS rate at 6, 12, and 24 months was 97.5%, 70.0%, and 34.6%, respectively. The results of the univariate analysis revealed that the type of pathology and GTV D90 were related to PFS rate (P<0.05). However, the type of pathology, GTV D90, age, and implantation site were related to OS rate (P<0.05). The results of the multivariate analysis revealed that the GTV D90 was related to PFS rate (P<0.05). The type of pathology and GTV D90 were related to OS r","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PO110","authors":"Juan Wang, Guohui Cao","doi":"10.1016/j.brachy.2023.06.211","DOIUrl":"https://doi.org/10.1016/j.brachy.2023.06.211","url":null,"abstract":"Purpose To investigate the prognostic value of neutrophil-lymphocyte ratio in patients with advanced lung cancer treated with radioactive iodine 125 seeds implantation. Methods From January 2017 to March 2021, 49 patients with advanced lung cancer received iodine 125 seed implantation in our hospital. use χ The influencing factors of clinical efficacy were analyzed. The optimal preoperative NLR limit was obtained by establishing the receiver operating characteristic curve (ROC). The clinicopathological factors were analyzed by logistic univariate analysis and multivariate survival analysis by binary logistics. Results The total effective rate of 49 patients 6 months after treatment was 65.31% (32 / 49). Univariate analysis showed that the maximum tumor diameter (χ2 = 6.69, P = 0.0097), postoperative D90 (χ2= 9.55, P = 0.002), preoperative NLR(χ2= 9.32, P = 0.0023). Multivariate analysis showed that postoperative D90 (P = 0.048) and preoperative NLR (P = 0.018) were independent prognostic factors of local effective rate after lung cancer seed implantation. Conclusions Radioactive iodine 125 seed implantation showed good efficacy in the treatment of patients with advanced lung cancer. Preoperative NLR and postoperative D90 were independent prognostic factors for the effective rate after lung cancer seed implantation, High NLR is a poor prognostic factor for lung cancer seed implantation. To investigate the prognostic value of neutrophil-lymphocyte ratio in patients with advanced lung cancer treated with radioactive iodine 125 seeds implantation. From January 2017 to March 2021, 49 patients with advanced lung cancer received iodine 125 seed implantation in our hospital. use χ The influencing factors of clinical efficacy were analyzed. The optimal preoperative NLR limit was obtained by establishing the receiver operating characteristic curve (ROC). The clinicopathological factors were analyzed by logistic univariate analysis and multivariate survival analysis by binary logistics. The total effective rate of 49 patients 6 months after treatment was 65.31% (32 / 49). Univariate analysis showed that the maximum tumor diameter (χ2 = 6.69, P = 0.0097), postoperative D90 (χ2= 9.55, P = 0.002), preoperative NLR(χ2= 9.32, P = 0.0023). Multivariate analysis showed that postoperative D90 (P = 0.048) and preoperative NLR (P = 0.018) were independent prognostic factors of local effective rate after lung cancer seed implantation. Radioactive iodine 125 seed implantation showed good efficacy in the treatment of patients with advanced lung cancer. Preoperative NLR and postoperative D90 were independent prognostic factors for the effective rate after lung cancer seed implantation, High NLR is a poor prognostic factor for lung cancer seed implantation.","PeriodicalId":93914,"journal":{"name":"Brachytherapy","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}